Kareem Jamani

708 total citations
37 papers, 305 citations indexed

About

Kareem Jamani is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Kareem Jamani has authored 37 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 11 papers in Oncology and 7 papers in Immunology. Recurrent topics in Kareem Jamani's work include Hematopoietic Stem Cell Transplantation (17 papers), Acute Myeloid Leukemia Research (7 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Kareem Jamani is often cited by papers focused on Hematopoietic Stem Cell Transplantation (17 papers), Acute Myeloid Leukemia Research (7 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Kareem Jamani collaborates with scholars based in Canada, United States and Egypt. Kareem Jamani's co-authors include Jan Storek, Andrew Daly, Faisal Khan, Poonam Dharmani‐Khan, Víctor H. Jiménez‐Zepeda, Mary E.D. Flowers, Peter Duggan, Tyler Williamson, Stephanie J. Lee and Douglas A. Stewart and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.

In The Last Decade

Kareem Jamani

31 papers receiving 304 citations

Peers

Kareem Jamani
Bendt Nielsen Denmark
Nicole Karras United States
HT Greinix Austria
AR Zander Germany
Kazutoshi Koike Japan
Shannon Palmer United States
Caroline L. Furness United Kingdom
MJ Cowan United States
Stefano Angelini Italy
Tsunehiko Komatsu Japan
Bendt Nielsen Denmark
Kareem Jamani
Citations per year, relative to Kareem Jamani Kareem Jamani (= 1×) peers Bendt Nielsen

Countries citing papers authored by Kareem Jamani

Since Specialization
Citations

This map shows the geographic impact of Kareem Jamani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kareem Jamani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kareem Jamani more than expected).

Fields of papers citing papers by Kareem Jamani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kareem Jamani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kareem Jamani. The network helps show where Kareem Jamani may publish in the future.

Co-authorship network of co-authors of Kareem Jamani

This figure shows the co-authorship network connecting the top 25 collaborators of Kareem Jamani. A scholar is included among the top collaborators of Kareem Jamani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kareem Jamani. Kareem Jamani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Murray, Alistair, Igor Novitzky‐Basso, Jonas Mattsson, et al.. (2024). Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease. Bone Marrow Transplantation. 59(6). 759–764. 4 indexed citations
3.
Law, Arjun, Kareem Jamani, Mohamed Elemary, et al.. (2024). Real-World Efficacy of Belumosudil in Treating Fibrotic Symptom Burden in Chronic Gvhd: Modified Lee Symptom Score Assessment after Multiple Treatment Failures. Blood. 144(Supplement 1). 7353–7353. 1 indexed citations
4.
Taylor, Mallory, Steve W. Cole, Ruta Brazauskas, et al.. (2023). Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis. Blood Advances. 7(22). 6830–6838. 5 indexed citations
5.
Puckrin, Robert, Kareem Jamani, & Víctor H. Jiménez‐Zepeda. (2023). Long‐term survivorship care after CAR‐T cell therapy. European Journal Of Haematology. 112(1). 41–50. 12 indexed citations
6.
Béland, Benjamin, Christopher Hahn, Kareem Jamani, et al.. (2023). P.035 Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti-muscle specific kinase antibodies. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50(s2). S67–S67.
7.
Puckrin, Robert, Catherine Leyshon, Peter Duggan, et al.. (2023). Corticosteroids as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplant recipients with calcineurin inhibitor intolerance. Cytotherapy. 25(10). 1101–1106.
8.
Cerquozzi, Sonia, Harold J. Olney, Anargyros Xenocostas, et al.. (2023). Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy. Leukemia Research. 133. 107374–107374. 6 indexed citations
9.
Abedin, Tasnima, S. Ali Naqvi, Hua Shen, et al.. (2022). Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation. Blood Advances. 6(3). 767–773. 7 indexed citations
10.
Ghosh, Sunita, Catherine Leyshon, Deonne Dersch‐Mills, et al.. (2022). Toward optimization of cyclosporine concentration target to prevent acute graft‐versus‐host disease following myeloablative allogeneic stem cell transplant. Clinical Transplantation. 36(8). e14732–e14732. 4 indexed citations
11.
Tripathi, Gaurav, Poonam Dharmani‐Khan, Robert Puckrin, et al.. (2022). Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease. Cytotherapy. 24(12). 1225–1231. 2 indexed citations
12.
Williamson, Tyler, Kareem Jamani, Ahsan Chaudhry, et al.. (2021). Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(1). 53.e1–53.e10. 15 indexed citations
13.
14.
Hazlewood, Glen, Caylib Durand, Susan G. Barr, et al.. (2021). Efficacy of Allogeneic Hematopoietic Cell Transplantation for Autoimmune Diseases. Transplantation and Cellular Therapy. 27(6). 489.e1–489.e9. 5 indexed citations
15.
Williamson, Tyler, Nicole L. Prokopishyn, Poonam Dharmani‐Khan, et al.. (2020). Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low‐dose total body irradiation, and rabbit antithymocyte globulin. Clinical Transplantation. 34(9). e14018–e14018. 11 indexed citations
16.
Cheng, Guang‐Shing, Louise Bondeelle, Ted Gooley, et al.. (2019). Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 26(2). 392–400. 20 indexed citations
17.
Chaudhry, Ahsan, Poonam Dharmani‐Khan, Daniel B. Gregson, et al.. (2019). High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era. Cytotherapy. 22(1). 27–34. 19 indexed citations
18.
Jamani, Kareem, Nicole L. Prokopishyn, Joanne Luider, et al.. (2018). Rabbit Antithymocyte Globulin Serum Levels: Factors Impacting the Levels and Clinical Outcomes Impacted by the Levels. Biology of Blood and Marrow Transplantation. 25(4). 639–647. 18 indexed citations
19.
Jamani, Kareem, Peter Duggan, Paola Neri, Nizar J. Bahlis, & Víctor H. Jiménez‐Zepeda. (2015). Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight. Leukemia & lymphoma. 57(3). 557–562. 3 indexed citations
20.
Podgorny, Peter, Yiping Liu, Poonam Dharmani‐Khan, et al.. (2014). Immune Cell Subset Counts Associated with Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 20(4). 450–462. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bendt Nielsen Breakdown of academic impact, for papers by Nicole Karras Breakdown of academic impact, for papers by HT Greinix Breakdown of academic impact, for papers by AR Zander Breakdown of academic impact, for papers by Kazutoshi Koike Breakdown of academic impact, for papers by Shannon Palmer Breakdown of academic impact, for papers by Caroline L. Furness Breakdown of academic impact, for papers by MJ Cowan Breakdown of academic impact, for papers by Stefano Angelini Breakdown of academic impact, for papers by Tsunehiko Komatsu
Rankless by CCL
2026